HMGCR Genotype

If you are weighing whether to start a statin, already taking one and unsure it is doing enough, or carry a family history of early heart disease, your HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) genotype is a piece of biological context that does not change once it is checked. The variants you inherited at this gene shape how much cholesterol your liver makes, how strongly statins lower your LDL, and how your long-term risk for several diseases lines up.

This is the gene that codes for the enzyme statins were designed to block. Reading your genotype is essentially reading a built-in, lifelong version of partial statin exposure. The result helps explain numbers you already see on your lipid panel and forecasts how your body is likely to respond to common cholesterol-lowering treatment.

What This Gene Actually Does

HMGCR is the instruction manual for an enzyme called HMG-CoA reductase, which runs the rate-limiting step of cholesterol production inside your cells. The enzyme converts a precursor molecule (HMG-CoA) into mevalonic acid, the first committed step of cholesterol assembly. It is most active in tissues that need to build a lot of cholesterol, including the liver.

Statins work by sitting in this enzyme's active pocket and slowing it down. Inherited variants in the HMGCR gene can quietly do something similar, nudging the enzyme's output up or down for life. That is why researchers study HMGCR genotypes as a natural experiment for what a lifetime of mild statin exposure looks like.

How Statins Will Likely Work for You

Certain HMGCR variants (such as rs17238484 and rs12916) are tied to lower LDL cholesterol and closely mimic the broader effect of statins on the blood. A separate variant, rs3846662, changes how the gene is spliced and predicts a weaker statin response. In one study of 100 adults with dyslipidemia, carriers of this variant had significantly smaller drops in total and non-HDL cholesterol on a statin than non-carriers. A related minor haplotype that includes rs17244841, rs17238540, and rs3846662 has been associated with a roughly 5 to 20% reduction in statin LDL-lowering response.

A rare frameshift mutation in the catalytic core of the gene has been documented in adults with type 2 diabetes who showed essentially no LDL response to high-dose atorvastatin. The mutation produced a truncated, non-functional enzyme, and these individuals were genuine non-responders. This is uncommon, but it illustrates how the gene's coding directly determines whether the standard drug has anything to grip.

What this means for you: if you carry a poor-response HMGCR variant, modest LDL drops on a standard statin dose are not necessarily a sign you are skipping doses or eating badly. You may need a higher dose, a more potent statin, or a different class of cholesterol-lowering drug entirely to hit your goal.

Heart Disease Risk

HMGCR variants that lower LDL also lower the lifetime odds of cardiovascular events, in roughly the same proportion as statins do per unit of LDL lowering. In a large genetic analysis of 112,772 adults, variants in HMGCR and PCSK9 (another cholesterol-handling gene) produced nearly identical protective effects on cardiovascular events for each 10 mg/dL drop in LDL cholesterol (odds ratio about 0.84 for each).

In a study of 1,273 people, the HMGCR variant rs12916 was specifically associated with premature triple-vessel coronary artery disease, suggesting some variants in this region also carry risk independent of standard LDL signals.

Type 2 Diabetes Risk

The same LDL-lowering variants that protect the heart appear to nudge diabetes risk in the wrong direction. A weighted HMGCR genetic risk score was tied to about 9% higher odds of type 2 diabetes (odds ratio 1.09, 95% CI 1.02 to 1.16). A separate analysis found each 10 mg/dL of LDL lowering through HMGCR variants was linked to roughly 13% higher diabetes odds (odds ratio 1.13, 95% CI 1.06 to 1.20). Carriers of one LDL-lowering allele in the same study also showed modestly higher body weight, waist circumference, fasting glucose, and insulin.

What this means for you: this is the same trade-off seen with statins themselves in randomized trials. If you are starting a statin and your HMGCR genotype suggests the LDL effect will be real, it is worth pairing the start of treatment with closer glucose monitoring.

Resolving the Heart-Diabetes Paradox

It is reasonable to ask how the same gene variant can both protect against heart attacks and raise diabetes risk. Recent and not yet widely replicated genetic work suggests the two effects do not travel through the same biological wire. Within the HMGCR region, the variants most strongly tied to LDL cholesterol and the ones most strongly tied to body weight appear to act through distinct causal paths. The cardiovascular benefit and the metabolic cost are real, but they may be partly separable signals, which is also why statin trials show net cardiovascular benefit despite the diabetes signal.

Kidney Function

Genetically predicted HMGCR inhibition (the kind your variants encode) has been associated with slightly lower kidney filtration in some analyses. A Mendelian randomization analysis estimated that a 50 mg/dL decrease in LDL through HMGCR variants corresponded to about a 1.67% decrease in eGFR (95% CI minus 2.20% to minus 1.13%). The signal is small, and a separate analysis found that the link between HMGCR-driven LDL lowering and kidney failure was no longer statistically significant after adjusting for type 2 diabetes, suggesting the kidney effect may be partly mediated through diabetes rather than a direct renal effect.

Cancer Associations

Genetically proxied HMGCR inhibition has been linked to lower odds of epithelial ovarian cancer in one major Mendelian randomization analysis, though a more recent 2024 study reported the opposite direction (higher ovarian cancer risk), so the ovarian cancer link should be considered unsettled. The same approach has linked HMGCR inhibition to lower breast cancer risk, particularly the estrogen receptor-positive type. A pharmacogenetic study of 4,187 adults found that the HMGCR variant rs12654264 strongly modified how protective statin use was against colorectal cancer, with carriers of certain genotypes deriving more benefit. These findings come from genetic association studies and do not establish that taking a statin will reduce cancer risk in any individual person.

Autoimmune and Hormonal Effects

Variants that mimic stronger HMGCR inhibition have been tied to higher risk of rheumatoid arthritis in at least one Mendelian randomization analysis, but other Mendelian randomization studies have found the opposite direction or no significant association, so this link is genuinely contested. The same approach has linked HMGCR inhibition to lower risk of ankylosing spondylitis, with an odds ratio of 0.57 (95% CI 0.38 to 0.85) per 1 mmol/L drop in LDL through HMGCR variants. In a study of 474 women with polycystic ovary syndrome, certain HMGCR variants modified insulin resistance and sex hormone binding globulin levels without changing whether women met PCOS criteria.

What This Test Will Not Tell You

This test reports your inherited variants at the HMGCR gene. It does not measure how much HMG-CoA reductase enzyme you actively produce day to day, your current cholesterol levels, or whether you have a statin-induced muscle problem. Anti-HMGCR autoantibodies, which can drive a severe statin-related muscle disease, are a different test entirely and are unrelated to your genotype.

When Results Can Be Misleading

A few things can complicate genetic results at this locus:

• Variant panel coverage: the assay only reads the specific HMGCR variants it is designed to detect. A clean result does not rule out rare HMGCR mutations (like frameshift variants tied to statin non-response) that fall outside the panel.
• Population-specific allele frequencies: many HMGCR studies have been conducted in adults of European ancestry, and effect sizes for some variants are stronger in certain populations. Some studies show race-related differences in how HMGCR variants influence LDL response to simvastatin.
• Direct-to-consumer vs clinical-grade testing: if you have seen an HMGCR result on a consumer DNA report, it should be confirmed on a clinical-grade assay before guiding treatment decisions. Independent analysis of direct-to-consumer raw data has found that about 40% of variants flagged in raw files are false positives on clinical confirmation.
• Variants of uncertain significance: not every coding change in this gene has a known clinical meaning. An unexpected variant call may need expert review before any action is taken.

This Is a One-Time Test

Your HMGCR genotype is fixed at birth and does not need to be repeated. There is no trend line to track and no schedule to follow for this specific test. The value comes from integrating the result into ongoing decisions over years, particularly around lipid management.

What does need ongoing tracking are the downstream lab markers this genotype helps interpret. A reasonable cadence is a baseline lipid panel (including ApoB and Lp(a)) with fasting glucose and HbA1c, repeated 3 to 6 months after any new cholesterol-lowering treatment, and at least annually thereafter. If you start a statin, an early follow-up lipid panel paired with your HMGCR genotype tells you whether you are getting the response your biology predicts.

What to Do With an Unexpected Result

If your HMGCR result suggests reduced statin responsiveness, treat it as a planning input rather than a verdict. The decision pathway depends on what other findings travel with it:

• Reduced-response variant plus high LDL or ApoB: a lipidologist or preventive cardiologist can help map out higher-potency statin options, ezetimibe combinations, or PCSK9-targeting therapy. Confirm rare variants with a second method before any major treatment shift.
• Reduced-response variant plus normal LDL: your standard lipids may already be in a good place, and the result mostly tells you what to expect if you ever need treatment. Continue baseline lipid tracking and add ApoB and Lp(a) for a fuller cardiovascular picture.
• Variants associated with diabetes signal: if you start or already take a statin, layer in fasting glucose, HbA1c, and fasting insulin tracking, and pay closer attention to weight and waist circumference changes.
• Family history of premature heart disease: encourage first-degree relatives to consider their own lipid and ApoB testing. Familial hypercholesterolemia genetic testing (LDLR, APOB, PCSK9) is a separate, complementary workup that may be relevant.

For most people, the HMGCR result is one panel in a larger lipid and cardiometabolic picture. It earns its keep when it explains why a statin worked less well than expected, when it shapes the choice of first-line therapy, or when it gives a head start to someone with a family pattern of early heart disease who has not yet seen abnormal labs.